The Role of CSTF2 in Cancer: from Technology to Clinical Application

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2024 Jan 3

PMID 38166492

Authors

Jiaxiang Ding

Yue Su

Youru Liu

Yuanyuan Xu

Dashuai Yang

Xuefeng Wang

Shuli Hao

Huan Zhou

Hongtao Li

Affiliations

Soon will be listed here.

Abstract

A protein called cleavage-stimulating factor subunit 2 (CSTF2, additionally called CSTF-64) binds RNA and is needed for the cleavage and polyadenylation of mRNA. CSTF2 is an important component subunit of the cleavage stimulating factor (CSTF), which is located on the X chromosome and encodes 557 amino acids. There is compelling evidence linking elevated CSTF2 expression to the pathological advancement of cancer and on its impact on the clinical aspects of the disease. The progression of cancers, including hepatocellular carcinoma, melanoma, prostate cancer, breast cancer, and pancreatic cancer, is correlated with the upregulation of CSTF2 expression. This review provides a fresh perspective on the investigation of the associations between CSTF2 and various malignancies and highlights current studies on the regulation of CSTF2. In particular, the mechanism of action and potential clinical applications of CSTF2 in cancer suggest that CSTF2 can serve as a new biomarker and individualized treatment target for a variety of cancer types.

Citing Articles

Expression of CSTF2 in oral squamous cell carcinoma and its relationship with immune infiltration and poor prognosis.

Aierken Z, Muhetaer M, Lei Z, Abudourousuli A Front Oral Health. 2025; 6:1548829.

PMID: 39989603 PMC: 11842344. DOI: 10.3389/froh.2025.1548829.

References

Galsky M, Pal S, Lin S, Ogale S, Zivkovic M, Simpson J . Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. Bladder Cancer. 2018; 4(2):227-238. PMC: 5929305. DOI: 10.3233/BLC-170149. View

Sun S, Hu S, Shang Y, Li L, Zhou H, Chen J . Relevance function of microRNA-708 in the pathogenesis of cancer. Cell Signal. 2019; 63:109390. DOI: 10.1016/j.cellsig.2019.109390. View

Miller K, Nogueira L, Devasia T, Mariotto A, Yabroff K, Jemal A . Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022; 72(5):409-436. DOI: 10.3322/caac.21731. View

Gilles H, Garbutt T, Landrum J . Hepatocellular Carcinoma. Crit Care Nurs Clin North Am. 2022; 34(3):289-301. DOI: 10.1016/j.cnc.2022.04.004. View

Zeidler R, de Freitas Soares B, Bader A, Giri S . Molecular epigenetic targets for liver diseases: current challenges and future prospects. Drug Discov Today. 2017; 22(11):1620-1636. DOI: 10.1016/j.drudis.2017.07.008. View

Feng Y, Dai X, Li X, Wang H, Liu J, Zhang J . EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif. 2012; 45(5):413-9. PMC: 6495284. DOI: 10.1111/j.1365-2184.2012.00837.x. View

Guo S, Deng C . Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation. Int J Biol Sci. 2018; 14(14):2083-2093. PMC: 6299363. DOI: 10.7150/ijbs.25720. View

Chen Y, Chen D, Wang Q, Xu Y, Huang X, Haglund F . Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. Front Immunol. 2022; 12:719105. PMC: 8801451. DOI: 10.3389/fimmu.2021.719105. View

Zhang S, Zhang X, Lei W, Liang J, Xu Y, Liu H . Genome-wide profiling reveals alternative polyadenylation of mRNA in human non-small cell lung cancer. J Transl Med. 2019; 17(1):257. PMC: 6686416. DOI: 10.1186/s12967-019-1986-0. View

10.

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

11.

Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):15-31. PMC: 3291787. DOI: 10.1517/14728222.2011.648617. View

12.

Xia Z, Donehower L, Cooper T, Neilson J, Wheeler D, Wagner E . Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3'-UTR landscape across seven tumour types. Nat Commun. 2014; 5:5274. PMC: 4467577. DOI: 10.1038/ncomms6274. View

13.

Connelly S, Manley J . A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. Genes Dev. 1988; 2(4):440-52. DOI: 10.1101/gad.2.4.440. View

14.

Yeh H, Yong J . Alternative Polyadenylation of mRNAs: 3'-Untranslated Region Matters in Gene Expression. Mol Cells. 2016; 39(4):281-5. PMC: 4844933. DOI: 10.14348/molcells.2016.0035. View

15.

Deka P, Rajan P, Perez-Canadillas J, Varani G . Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human Cstf-64 protein. J Mol Biol. 2005; 347(4):719-33. DOI: 10.1016/j.jmb.2005.01.046. View

16.

Condorelli D, Privitera A, Barresi V . Chromosomal Density of Cancer Up-Regulated Genes, Aberrant Enhancer Activity and Cancer Fitness Genes Are Associated with Transcriptional Cis-Effects of Broad Copy Number Gains in Colorectal Cancer. Int J Mol Sci. 2019; 20(18). PMC: 6770609. DOI: 10.3390/ijms20184652. View

17.

Fakhry C, Zevallos J, Eisele D . Imbalance Between Clinical and Pathologic Staging in the Updated American Joint Commission on Cancer Staging System for Human Papillomavirus-Positive Oropharyngeal Cancer. J Clin Oncol. 2017; 36(3):217-219. DOI: 10.1200/JCO.2017.75.2063. View

18.

Kari C, Chan T, Rocha de Quadros M, Rodeck U . Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003; 63(1):1-5. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View